tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Stryker (SYK) and Verve Therapeutics (VERV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stryker (SYKResearch Report) and Verve Therapeutics (VERVResearch Report).

Stryker (SYK)

In a report released today, Robbie Marcus from J.P. Morgan maintained a Buy rating on Stryker, with a price target of $240.00. The company’s shares closed last Tuesday at $204.41.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 8.1% and a 48.6% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Baxter International, and Intuitive Surgical.

Currently, the analyst consensus on Stryker is a Moderate Buy with an average price target of $241.59, a 19.3% upside from current levels. In a report issued on July 12, Nephron also initiated coverage with a Buy rating on the stock with a $240.00 price target.

See today’s best-performing stocks on TipRanks >>

Verve Therapeutics (VERV)

J.P. Morgan analyst Eric Joseph maintained a Hold rating on Verve Therapeutics on July 25 and set a price target of $36.00. The company’s shares closed last Tuesday at $28.51.

According to TipRanks.com, Joseph is a 2-star analyst with an average return of 0.8% and a 49.4% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Rocket Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Verve Therapeutics is a Strong Buy with an average price target of $58.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SYK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More